

primary studies - published RCT

The effects of an intensive behavior and nutrition intervention compared to standard of care on weight outcomes in CF.

Code: PM20812240

Year: 2011 Date: 2014

Author: Stark LJ

Study design (if review, criteria of inclusion for studies)

Randomized, double-blind, placebo-controlled study

Participants

CF patients aged ≥ 6 years with mild to moderate lung disease. 420 (155 children, 265 adults) of the planned 600 patients were randomized

Interventions

Leukotriene B4 (LTB4)-receptor antagonist BIIL 284 BS vs placebo once daily for 24 weeks.

Outcome measures

Co-primary endpoints were change in FEV1 and incidence of pulmonary exacerbation.

Main results

After 420 (155 children, 265 adults) of the planned 600 patients were randomized, the trial was terminated after a planned interim analysis revealed a significant increase in pulmonary related serious adverse events (SAEs) in adults receiving BIIL 284 BS. Final analysis revealed SAEs in 36.1% of adults receiving BIIL 284 BS vs. 21.2% receiving placebo ($p=0.007$), and in 29.6% of children receiving BIIL 284 BS vs. 22.9% receiving placebo ($p=0.348$). In adults, the incidence of protocol-defined pulmonary exacerbation was greater in those receiving BIIL 284 BS than in those receiving placebo (33.1% vs. 18.2% respectively; $p=0.005$). In children, the incidence of protocol-defined pulmonary exacerbation was 19.8% in the BIIL 284 BS arm, and 25.7% in the placebo arm ($p=0.38$).

Authors' conclusions

While the cause of increased SAEs and exacerbations due to BIIL 284 BS is unknown, the outcome of this trial provides a cautionary tale for the administration of potent anti-inflammatory compounds to individuals with chronic infections, as the potential to significantly suppress the inflammatory response may increase the risk of infection-related adverse events.

<http://dx.doi.org/10.1002/ppul.21322>

See also

Pediatr Pulmonol. 2011 Jan;46(1):31-5. doi: 10.1002/ppul.21322. Epub 2010 Sep 1.

Keywords

Amelubant; Leukotriene Antagonists; pharmacological_intervention; Respiratory Tract Diseases;